🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsRetatrutide and blood pressure — looking for input Page 3

Retatrutide and blood pressure — looking for input

AmyNC_wife Sun, Feb 8, 2026 at 1:07 PM 12 replies 961 viewsPage 3 of 3
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Feb 12, 2026 at 4:48 PM#11
pat_auckland said:
I'm 55 years old and want to share my perspective on cardiovascular risk as an older member of this community.

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
28 1EndoResFellow, PharmacoVig_BOS, SurmountFan_IN and 25 others
Reply Quote Save Share Report
josh_phd_bmore
Member
389
1,678
Jul 2024
Baltimore, MD
Feb 15, 2026 at 12:42 AM#12
anders_CPH said:
Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale.

Thank you for spelling out the reasoning rather than just the conclusion. Sending this to two other people who asked me the same thing last week.

29 2Dr.ObesityLA, NurseKim_ATL, paul_denver and 26 others
Reply Quote Save Share Report
pete_RVA
Member
178
890
Dec 2024
Richmond, VA
Feb 17, 2026 at 8:35 AM#13
pat_auckland said:
I'm 55 years old and want to share my perspective on cardiovascular risk as an older member of this community.

I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.

30 3Admin, Dr.Martinez, mike_mod and 27 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
hank_denver
Member
278
1,234
Sep 2024
Denver, CO
Feb 19, 2026 at 4:27 PM#14
AmyNC_wife said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.
AmyNC_wife said:
...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

31 4fiona_VT, denise_HTX, raj_cambridge and 28 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Feb 22, 2026 at 12:18 AM#15

Moderator note: the sourcing question belongs in the vendor section and has been split out. Thread quality here is what the rules are for. Keep it up.

Last edited: Feb 22, 2026 at 4:18 AM
32 5PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 29 others
Reply Quote Save Share Report

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register